NCT03418038 2026-03-18
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Phase 2 Recruiting
Clinical Trials
1,846 trialsNCT07480850 2026-03-18
Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting
NCT07480863 2026-03-18
Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting
NCT03590171 2026-03-17
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
Charite University, Berlin, Germany
Phase 2 Recruiting
NCT05478512 2026-03-17
VIS
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Active not recruiting
NCT07021989 2026-03-17
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
University of California, San Francisco
Phase 2 Not yet recruiting
NCT04703686 2026-03-16
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT05615636 2026-03-16
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05783596 2026-03-16
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06561074 2026-03-16
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04644016 2026-03-13
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04676360 2026-03-13
Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma
Massachusetts General Hospital
Phase 2 Terminated
NCT05453500 2026-03-13
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
University of Washington
Phase 2 Recruiting
NCT06442475 2026-03-13
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
University of Washington
Phase 2 Recruiting
NCT06510309 2026-03-13
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
Beth Israel Deaconess Medical Center
Phase 2 Recruiting
NCT06510361 2026-03-13
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Beth Israel Deaconess Medical Center
Phase 2 Recruiting
NCT06572618 2026-03-13
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
City of Hope Medical Center
Phase 2 Recruiting
NCT06738368 2026-03-13
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
University of Washington
Phase 2 Recruiting
NCT06784726 2026-03-13
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
University of Washington
Phase 2 Recruiting
NCT07218510 2026-03-13
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
City of Hope Medical Center
Phase 2 Recruiting
NCT03970096 2026-03-12
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT06043323 2026-03-12
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT00492050 2026-03-11
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06263491 2026-03-11
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07164469 2026-03-11
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT03458260 2026-03-10
Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT07460362 2026-03-10
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
Peking University Third Hospital
Phase 2 Recruiting
NCT07178912 2026-03-09
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT07457177 2026-03-09
Phaes â…¡ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL
Beijing Tongren Hospital
Phase 2 Not yet recruiting
NCT04128501 2026-03-06
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05306301 2026-03-06
Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Active not recruiting
NCT05502250 2026-03-06
HOVON164HL
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 2 Active not recruiting
NCT07030699 2026-03-06
ECLAT
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT02339922 2026-03-05
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
Phase 2 Active not recruiting
NCT03506373 2026-03-05
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
Mayo Clinic
Phase 2 Terminated
NCT05268003 2026-03-05
A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05672355 2026-03-05
A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia
City of Hope Medical Center
Phase 2 Recruiting
NCT05800366 2026-03-05
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06416085 2026-03-05
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer
University Health Network, Toronto
Phase 2 Active not recruiting
NCT06651177 2026-03-05
TAB
University of Cincinnati
Phase 2 Recruiting
NCT06698003 2026-03-05
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07042438 2026-03-05
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
City of Hope Medical Center
Phase 2 Recruiting
NCT07451652 2026-03-05
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Hospital Universitario Dr. Jose E. Gonzalez
Phase 2 Recruiting
NCT07453095 2026-03-05
Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy
Fondazione Italiana Linfomi - ETS
Phase 2 Not yet recruiting
NCT03849651 2026-03-04
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT04802590 2026-03-04
Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
The Lymphoma Academic Research Organisation
Phase 2 Active not recruiting
NCT07448324 2026-03-04
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT05565105 2026-03-03
CD34+ Transplants for Leukemia and Lymphoma
Baptist Health South Florida
Phase 2 Not yet recruiting
NCT06486051 2026-03-03
ENABLE-2
Malaghan Institute of Medical Research
Phase 2 Recruiting
NCT03514017 2026-03-02
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated